Microscopic polyangiitis overview: Difference between revisions

Jump to navigation Jump to search
Line 3: Line 3:
{{CMG}} ; {{AE}} {{VKG}}
{{CMG}} ; {{AE}} {{VKG}}
==Overview==
==Overview==
The early case reports of [[Microscopic polyangiitis]] provide a historical context and foundation for better understanding of the current concepts of these [[Disease|diseases]] Microscopic polyangiitis.[[Microscopic polyangiitis]] was first introduced by Dr. Friedrich Wohlwill, a German [[neuropathologist]], who described two patients with [[Transmural care|transmural]] periarteritis with [[glomerulonephritis]] in 1923.Historically, most forms of [[vasculitis]] like microscopic polyangiitis described subsequently classified on the basis of features similar to or distinct from [[polyarteritis]].According to The International Chapel Hill Consensus Conference (CHCC) criteria based on Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) into [[granulomatosis with polyangiitis]] (GPA), [[microscopic polyangiitis]] (MPA), including renal-limited vasculitis (RLV), and [[eosinophilic granulomatosis with polyangiitis]] (EGPA, [[Churg-Strauss syndrome|Churg-Strauss]]).The [[pathogenesis]] of [[Microscopic polyangiitis]] is currently not fully understood. However, certain [[Hypothesis|hypothesizes]] have been made to determine possible factors that may trigger the disease such as environmental factors and [[Anti-neutrophil cytoplasmic antibody|anti-neutrophil cytoplasmic antibodies.]] [[Capillary|Capillaries]] and [[venules]] are involved in the [[pathogenesis]] of [[microscopic polyangiitis]].The paucity of [[immunoglobulin]] deposition is shown in [[Immunohistochemical staining|Immunohistochemical]] staining.There are no known direct causes for [[Microscopic polyangiitis]].[[Microscopic polyangiitis]] can affect individuals from all ethnicities and of any [[age]] group.[[Vasculitis]] is a common term that refers to [[inflammation]] of the [[Blood vessel|blood vessels]] in the body.When the [[inflammation]] progress it lead to weakening and stretch of the [[Blood vessel|blood vessels]] and forms a an [[aneurysm]].Microscopic polyangiitis is not a [[cancer]], not [[contagious]], and it does not usually occur within families.
The early case reports of [[Microscopic polyangiitis]] provide a historical context and foundation for better understanding of the current concepts of these [[Disease|diseases]] Microscopic polyangiitis.[[Microscopic polyangiitis]] was first introduced by Dr. Friedrich Wohlwill, a German [[neuropathologist]], who described two patients with [[Transmural care|transmural]] periarteritis with [[glomerulonephritis]] in 1923.Historically, most forms of [[vasculitis]] like microscopic polyangiitis described subsequently classified on the basis of features similar to or distinct from [[polyarteritis]].According to The International Chapel Hill Consensus Conference (CHCC) criteria based on Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) into [[granulomatosis with polyangiitis]] (GPA), [[microscopic polyangiitis]] (MPA), including renal-limited vasculitis (RLV), and [[eosinophilic granulomatosis with polyangiitis]] (EGPA, [[Churg-Strauss syndrome|Churg-Strauss]]).The [[pathogenesis]] of [[Microscopic polyangiitis]] is currently not fully understood. However, certain [[Hypothesis|hypothesizes]] have been made to determine possible factors that may trigger the disease such as environmental factors and [[Anti-neutrophil cytoplasmic antibody|anti-neutrophil cytoplasmic antibodies.]] [[Capillary|Capillaries]] and [[venules]] are involved in the [[pathogenesis]] of [[microscopic polyangiitis]].The paucity of [[immunoglobulin]] deposition is shown in [[Immunohistochemical staining|Immunohistochemical]] staining.There are no known direct causes for [[Microscopic polyangiitis]].[[Microscopic polyangiitis]] can affect individuals from all ethnicities and of any [[age]] group.[[Vasculitis]] is a common term that refers to [[inflammation]] of the [[Blood vessel|blood vessels]] in the body.When the [[inflammation]] progress it lead to weakening and stretch of the [[Blood vessel|blood vessels]] and forms a an [[aneurysm]].Microscopic polyangiitis is not a [[cancer]], not [[contagious]], and it does not usually occur within families.The [[prevalence]] of [[Microscopic polyangiitis]] higher in Southern European countries and Asia.The incidence of GPA was similar to that of MPA.MPO‐[[Anti-neutrophil cytoplasmic antibody|ANCAs]] when positive in a patient was a marker of poor [[prognosis]] in the population of patients with AAV.

Revision as of 17:43, 30 April 2018

Microscopic polyangiitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Microscopic polyangiitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Microscopic polyangiitis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Microscopic polyangiitis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Microscopic polyangiitis overview

CDC on Microscopic polyangiitis overview

Microscopic polyangiitis overview in the news

Blogs on Microscopic polyangiitis overview

Directions to Hospitals Treating Type chapter name here

Risk calculators and risk factors for Microscopic polyangiitis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

The early case reports of Microscopic polyangiitis provide a historical context and foundation for better understanding of the current concepts of these diseases Microscopic polyangiitis.Microscopic polyangiitis was first introduced by Dr. Friedrich Wohlwill, a German neuropathologist, who described two patients with transmural periarteritis with glomerulonephritis in 1923.Historically, most forms of vasculitis like microscopic polyangiitis described subsequently classified on the basis of features similar to or distinct from polyarteritis.According to The International Chapel Hill Consensus Conference (CHCC) criteria based on Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) into granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), including renal-limited vasculitis (RLV), and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss).The pathogenesis of Microscopic polyangiitis is currently not fully understood. However, certain hypothesizes have been made to determine possible factors that may trigger the disease such as environmental factors and anti-neutrophil cytoplasmic antibodies. Capillaries and venules are involved in the pathogenesis of microscopic polyangiitis.The paucity of immunoglobulin deposition is shown in Immunohistochemical staining.There are no known direct causes for Microscopic polyangiitis.Microscopic polyangiitis can affect individuals from all ethnicities and of any age group.Vasculitis is a common term that refers to inflammation of the blood vessels in the body.When the inflammation progress it lead to weakening and stretch of the blood vessels and forms a an aneurysm.Microscopic polyangiitis is not a cancer, not contagious, and it does not usually occur within families.The prevalence of Microscopic polyangiitis higher in Southern European countries and Asia.The incidence of GPA was similar to that of MPA.MPO‐ANCAs when positive in a patient was a marker of poor prognosis in the population of patients with AAV.